Results 101 to 110 of about 1,551 (185)

Givosiran per al tractament de la porfíria hepàtica aguda

open access: yes, 2022
Les porfíries són un grup de malalties metabòliques causades per una pèrdua de funcionalitat en els enzims que participen en la biosíntesi del grup hemo. Es classifiquen en funció de les principals manifestacions clíniques (neurològiques o cutànies) i del teixit on es produeix l’alteració enzimàtica (fetge o medul·la òssia).
openaire   +1 more source

Small interfering RNA: Discovery, pharmacology and clinical development—An introductory review [PDF]

open access: yes, 2022
Addison, Melisande L.   +3 more
core   +1 more source

Nucleic Acid Conjugates: Unlocking Therapeutic Potential [PDF]

open access: yes
Nucleic acids have emerged as a powerful class of therapeutics. Through simple base pair complementarity, nucleic acids allow the targeting of a variety of pathologically relevant proteins and RNA molecules.
Booth, Michael J., Kashyap, Disha
core   +2 more sources

Psychiatric Symptoms in Acute Intermittent Porphyria - Case Report and Course of Treatment Using Placebo [PDF]

open access: yes
Introduction: Acute intermittent porphyria is a disease inherited in an autosomal dominant manner, occurring with a frequency of 1:75,000 people.
Dominika Prystacka-Szar   +3 more
core   +1 more source

Oligonucleotides: evolution and innovation [PDF]

open access: yes
Oligonucleotides, comprising single or double strands of RNA or DNA, are vital chemical compounds used in various laboratory and clinical applications. They represent a significant class of therapeutics with a rapidly expanding range of uses.
Al Musaimi O
core  

Home - About - Disclaimer - Privacy